article thumbnail

STAT+: Boehringer Ingelheim layoffs are a sign of dysfunctional Humira biosimilar market

STAT

WASHINGTON —  Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive versions of the blockbuster, the company confirmed. List prices of Humira biosimilars are as much as 85% lower. 

article thumbnail

STAT+: Thanks to CVS, a biosimilar version of AbbVie’s Humira is grabbing huge market share

STAT

The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment, one of the best-selling medicines in the U.S., However, Hyrimoz is jointly marketed with Cordavis, a new subsidiary that CVS created last August specifically to sell any number of biosimilar medicines in the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Virtual Event: March of the Biosimilars

STAT

Several biosimilar versions of Humira, which for years has been the world’s best-selling medicine, entered the U.S. Editor’s note: A livestream of this event will be embedded below at 1 p.m. market over the past year. What has that meant for insurance coverage and the way drugmakers are marketing these medicines?

article thumbnail

STAT+: Pharmalittle: We’re reading about CVS and Humira biosimilars, Schumer’s broken insulin promise, and more

STAT

… The number of new prescriptions written for biosimilar versions of the Humira rheumatoid arthritis treatment, one of the best-selling medicines in the U.S., However, Hyrimoz is jointly marketed with Cordavis, a new subsidiary that CVS created last August specifically to sell biosimilar medicines in the U.S.

article thumbnail

Opinion: STAT+: A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira

STAT

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was  followed by  eight additional adalimumab biosimilar launches. Biosimilars  are safe and effective treatments referencing biologic drugs. They If they fail to act, the U.S.

article thumbnail

Opinion: STAT+: The problem with potential changes to the biosimilar regulatory framework

STAT

Biosimilars are no longer a new and untested class of medicines. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S.,    37 biosimilars  have come to market offering the potential to increase patient choice and cost savings.

article thumbnail

STAT+: Biosimilars haven’t always yielded lower out-of-pocket costs for patients, study finds

STAT

Two years after biosimilars became available in the U.S., In addition, patients who used biosimilars often did not pay lower out-of-pocket costs than those who were given brand-name biologic medicines. “The whole purpose of biosimilars was to introduce competition into the marketplace and lead the [U.S.]